Jatenzo Access Challenges: What Providers and Prescribers Need to Know in 2026

Jatenzo (testosterone undecanoate) represents a meaningful clinical advance in testosterone replacement therapy — an oral capsule that bypasses first-pass hepatic metabolism through intestinal lymphatic absorption. But for many prescribers in 2026, the clinical decision to prescribe Jatenzo is only the beginning of the challenge. Insurance barriers, patient cost burden, and pharmacy access issues can all derail treatment continuity.

This clinical briefing covers the current access landscape for Jatenzo in 2026, including regulatory updates, prior authorization guidance, formulary positioning, and tools your practice can use to support patients in filling their prescriptions.

Regulatory Update: Boxed Warning for Blood Pressure Removed July 2025

In July 2025, the FDA removed the boxed warning regarding blood pressure increases from Jatenzo's prescribing information. This is a clinically meaningful update: the boxed warning had been a significant factor in prescribing hesitation and had made prior authorization more difficult with some payers.

However, clinicians should note that blood pressure elevation remains a listed warning and precaution. The prescribing information still directs monitoring of blood pressure approximately 3 weeks after initiation or dose change. Jatenzo is still not recommended in patients with uncontrolled hypertension, and elevated BP remains an indication to reassess the risk-benefit ratio.

Current Availability and Supply Status

Jatenzo is not on the FDA's official drug shortage list. Supply from Tolmar, Inc. is maintained. However, the drug's access profile is complex:

Pharmacy stocking: Most retail chain pharmacies do not stock Jatenzo routinely. Patients often need to request a special order (1–3 business days) or use a specialty pharmacy.

Insurance coverage: Most plans require prior authorization. Jatenzo is frequently Tier 3 or non-formulary. Step therapy requirements are common. Medicare Part D plans generally do not cover without formulary exception.

Cost without coverage: $1,314–$1,658+ per month at retail. Tolmar's patient support program offers $185/month cash pricing and $0/month for eligible commercially insured patients via copay card.

Prior Authorization: What Insurers Typically Require

Documentation that typically supports a successful prior authorization for Jatenzo includes:

Two separate morning serum testosterone values below 300 ng/dL (or below lab reference range)

Confirmed diagnosis of primary or hypogonadotropic hypogonadism (not age-related decline)

Documentation of trial and failure, intolerance, or contraindication to generic injectable testosterone AND generic topical testosterone gel

Clinical rationale for oral route (e.g., patient preference, injection phobia, skin conditions precluding topical use, transfer risk concerns)

Dosage within FDA-labeled range (158 mg to 396 mg twice daily with food)

Clinical Considerations for Prescribing Jatenzo

Key clinical considerations when initiating or managing Jatenzo therapy in 2026:

Dose titration: Start at 237 mg twice daily with food. Measure serum testosterone 6 hours after the morning dose, at least 7 days after initiation or dose change. Titrate between 158 mg and 396 mg (two 198 mg capsules) twice daily based on response.

Blood pressure: Monitor BP approximately 3 weeks after initiation or dose change. Jatenzo increased ambulatory systolic/diastolic BP by an average of 4.9/2.5 mm Hg in clinical trials. 7% of patients required initiation or intensification of antihypertensive therapy.

Hematocrit: Monitor approximately every 3 months. If elevated, hold Jatenzo until hematocrit decreases to acceptable levels. 4.8% of patients in the pivotal trial had hematocrit increases.

Prostate: Evaluate for prostate cancer before initiation. Monitor PSA periodically. Jatenzo is contraindicated in men with known or suspected prostate cancer.

Drug interactions: May require INR/PT monitoring adjustments with warfarin. Monitor blood glucose in diabetic patients. Avoid combining with medications that raise blood pressure (NSAIDs, decongestants, corticosteroids).

Managing the Broader Testosterone TRT Context

Injectable testosterone cypionate remains in intermittent shortage as of early 2026. When patients are switched to Jatenzo as an alternative to injections, consider the following transition guidance:

Start Jatenzo at the standard 237 mg twice daily; do not attempt to dose-match to the patient's previous injection regimen directly

Check testosterone levels 7–14 days after initiating Jatenzo (at 6 hours post-morning dose) and titrate accordingly

Counsel patients that oral absorption may vary with meal fat content — instruct them to take each dose with a meal consistently

Tools to Help Your Patients Access Jatenzo

Pharmacy access is one of the most common points of friction for Jatenzo patients. medfinder for Providers allows your practice to identify pharmacies near a patient with confirmed stock or ordering capability for Jatenzo before you send the prescription — reducing back-and-forth and delays.

Additionally, make sure your staff is familiar with the Jatenzo Support program from Tolmar: the copay card for commercially insured patients, the $150/month option for those whose coverage is denied, and the $185/month cash patient program. Routing patients to these programs at the point of prescribing can prevent abandonment at the pharmacy.